• May 20, 2013
    Zoetis Inc., formerly the animal health business unit of Pfizer, today announced a gift of $100,000 for Salmonella research to Texas Tech University, College of Agricultural Sciences and Natural Resources, Department of Animal and Food Sciences. The research gift will help provide resources to better understand and describe the ecology of Salmonella in cattle populations and to discover and evaluate tools that might ultimately result in a safermore...
  • May 16, 2013
    MADISON, N.J.--(BUSINESS WIRE)--Zoetis, Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved APOQUEL® (oclacitinib tablet) for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. Developed by Zoetis, APOQUEL is the first Janus kinase (JAK)more...
  • April 30, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., today reported its financial results for the first quarter of 2013. The company reported revenues of $1.09 billion for the first quarter, an increase of 4% from the first quarter of 2012. Revenues reflected an operational2 increase of 5%, with foreign currency having a negative impact of 1%. Net income for the first quarter of 2013 was $140 million, or $0.28 permore...
  • April 18, 2013
    Zoetis Inc., formerly the animal health business unit of Pfizer Inc., today announced the first recipients of the company’s Excellence in Dermatology™ Research Grant program. The objective of the new program is to support research in the area of basic science diagnosing and treating dermatologic conditions in dogs and cats. Investigators from the University of Pennsylvania and Johns Hopkins University will receive one grant to pursuemore...
  • April 15, 2013
    ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the U.S. Department of Agriculture (USDA) has approved a newly-enhanced version of the WITNESS® HW Heartworm Antigen Test kit for dogs and cats. Launched today, the enhanced WITNESS HW test kit is now available to veterinarians nationwide. Enhancements to the biologics, including test antibodies, improvements to the buffer and sample pad and improve themore...
  • March 28, 2013
    MADISON, N.J.--(BUSINESS WIRE)--The Board of Directors of ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a second-quarter dividend payable to holders of the company’s Class A common stock and Class B common stock of $0.065 per share. The dividend is to be paid on June 6, 2013, to holders of record on May 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customersmore...
  • March 26, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, April 30, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and themore...
  • March 22, 2013
    Zoetis, formerly Pfizer Animal Health, announces the return of the Cattle Call grant program and is accepting research proposals for improving cattle reproduction or developing models for managing cattle pain. The Cattle Call supports the development of new products and services that improve the health and productivity of beef and dairy cattle. In 2013, Zoetis will fund one or more researchers with a grant of up to $150,000, withmore...
  • February 6, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing.Zoetis did not receive any of the proceeds of the offering. Following the completion of themore...
  • January 31, 2013
    MADISON, N.J.--ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the pricing of its initial public offering of 86,100,000 shares of its Class A common stock at $26 per share. The shares are expected to begin trading tomorrow, Feb. 1, on the New York Stock Exchange under the symbol “ZTS.” Zoetis will not receive any of the proceeds of the offering. Following the completion of the initial public offering,more...